Lesson plan

TCB-2

TCB-2, also known as 2CBCB or 2C-BCB, is a putative psychedelic drug of the phenethylamine, 2C, and benzocyclobutene families related to 2C-B. It is a cyclized phenethylamine and is the derivative of 2C-B in which the β position has been connected to the 6 position by a methylene bridge to form a benzocyclobutene ring system. It is unclear whether TCB-2 produces hallucinogenic effects in humans and its route of administration and properties such as dose and duration are unknown. The drug is a highly potent serotonin receptor agonist, including of the serotonin 5-HT 2A receptor among others. TCB-2 produces psychedelic-like effects in animals. It may be among the most potent known serotonin 5-HT 2A receptor agonists and psychedelic phenethylamines. TCB-2 is often employed as its more potent and selective enantiomer (R)-TCB-2 in scientific research. TCB-2 was first described in the scientific literature by Thomas McLean and colleagues of the lab of David E. Nichols at Purdue University in 2006. It was encountered as a novel designer drug by 2018, though it appears to be very rare. The drug is not an explicitly controlled substance in the United States and is fully legal for use in scientific research in this country. TCB-2 was suggested as an alternative and replacement of the widely employed DOI for use in research in 2025.

Back to article

Article summary

TCB-2, also known as 2CBCB or 2C-BCB, is a putative psychedelic drug of the phenethylamine, 2C, and benzocyclobutene families related to 2C-B. It is a cyclized phenethylamine and is the derivative of 2C-B in which the β position has been connected to the 6 position by a methylene bridge to form a benzocyclobutene ring system. It is unclear whether TCB-2 produces hallucinogenic effects in humans and its route of administration and properties such as dose and duration are unknown. The drug is a highly potent serotonin receptor agonist, including of the serotonin 5-HT 2A receptor among others. TCB-2 produces psychedelic-like effects in animals. It may be among the most potent known serotonin 5-HT 2A receptor agonists and psychedelic phenethylamines. TCB-2 is often employed as its more potent and selective enantiomer (R)-TCB-2 in scientific research. TCB-2 was first described in the scientific literature by Thomas McLean and colleagues of the lab of David E. Nichols at Purdue University in 2006. It was encountered as a novel designer drug by 2018, though it appears to be very rare. The drug is not an explicitly controlled substance in the United States and is fully legal for use in scientific research in this country. TCB-2 was suggested as an alternative and replacement of the widely employed DOI for use in research in 2025.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.